Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.38M Buy
7,080
+108
+2% +$22.4K 0.03% 527
2026
Q1
$1.57M Buy
6,972
+1,218
+21% +$304K 0.04% 416
2025
Q4
$1.39M Sell
5,754
-1,418
-20% -$363K 0.03% 506
2025
Q3
$1.97M Buy
+7,172
New +$1.96M 0.05% 347
2025
Q1
$1.33M Buy
5,919
+279
+5% +$65.1K 0.04% 380
2024
Q4
$1.29M Sell
5,640
-92
-2% -$22.2K 0.04% 360
2024
Q3
$1.4M Buy
5,732
+2,806
+96% +$627K 0.05% 314
2024
Q2
$560K Buy
2,926
+1,223
+72% +$248K 0.02% 509
2024
Q1
$337K Buy
1,703
+90
+6% +$16.5K 0.02% 520
2023
Q4
$277K Sell
1,613
-378
-19% -$58.1K 0.02% 558
2023
Q3
$294K Buy
1,991
+141
+8% +$25.5K 0.02% 497
2023
Q2
$404K Sell
1,850
-9
-0.5% -$2.01K 0.03% 422
2023
Q1
$407K Buy
1,859
+690
+59% +$150K 0.03% 410
2022
Q4
$243K Sell
1,169
-30
-3% -$6.59K 0.02% 457
2022
Q3
$262K Buy
1,199
+99
+9% +$22.5K 0.03% 444
2022
Q2
$231K Buy
1,100
+118
+12% +$25.1K 0.02% 461
2022
Q1
$238K Buy
982
+49
+5% +$11.9K 0.02% 506
2021
Q4
$243K Buy
+933
New +$242K 0.02% 497
2021
Q1
Sell
-1,039
Closed -$221K 528
2020
Q4
$221K Buy
+1,039
New +$207K 0.03% 424

Other funds holding RMD

Caprock Group's RMD Position: Q2 2026 in Review

Caprock Group increased its ResMed (RMD) stake by 1.5% in Q2 2026, buying an estimated $22.4K and bringing the position to 7,080 shares worth $1.38M. The position accounts for 0.03% of the portfolio, ranked #527.

Caprock Group first reported a position in RMD in Q4 2020 and has held it in 19 quarters since. The position peaked at $1.97M in Q3 2025. 882 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • Caprock Group held 7,080 shares of ResMed worth $1.38M as of Q2 2026.
  • Caprock Group bought 108 ResMed shares in Q2 2026, an estimated $22.4K.
  • ResMed made up 0.03% of Caprock Group's portfolio in Q2 2026, its #527 holding.
  • Caprock Group first reported a position in ResMed in Q4 2020 and has held it in 19 quarters since.
  • Caprock Group's ResMed position peaked at $1.97M in Q3 2025.
  • 882 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Caprock Group's 13F filing for Q2 2026, filed 27 Jul 2026.